Abstract
Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the leading genetic cause of Parkinson's disease (PD). LRRK2 is predicted to contain kinase and GTPase enzymatic domains, with recent evidence suggesting that the kinase activity of LRRK2 is central to the pathogenic process associated with this protein. The GTPase domain of LRRK2 plays an important role in the regulation of kinase activity. To investigate how the GTPase domain might be related to disease, we examined the GTP binding and hydrolysis properties of wild type and a mutant form of LRRK2. We show that LRRK2 immunoprecipitated from cells has a detectable GTPase activity that is disrupted by a familial mutation associated with PD located within the GTPase domain, R1441C.
MeSH Terms
Amino Acid Substitution
Animals
COS Cells
Chlorocebus aethiops
GTP Phosphohydrolases/genetics,metabolism
Guanosine Diphosphate/metabolism
Guanosine Triphosphate/metabolism
Humans
Hydrolysis
Immunoblotting
Immunoprecipitation
Kinetics
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Mutation
Parkinson Disease/enzymology,genetics
Protein Binding
Protein Serine-Threonine Kinases/genetics,metabolism
Chemicals
Guanosine Diphosphate
Guanosine Triphosphate
LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Protein Serine-Threonine Kinases
GTP Phosphohydrolases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Lewis Patrick A
Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892-3707, USA.
Greggio Elisa
Beilina Alexandra
Jain Shushant
Baker Acacia
Cookson Mark R
References (14)
14 references, click to expand
-
Roc, a Ras/GTPase domain in complex proteins.
Biochim Biophys Acta. 2003 Dec 7;1643(1-3):5-10
PMID: 14654223
-
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
Neuron. 2004 Nov 18;44(4):595-600
PMID: 15541308
-
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
Neuron. 2004 Nov 18;44(4):601-7
PMID: 15541309
-
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
Lancet. 2005 Jan 29-Feb 4;365(9457):410-2
PMID: 15680455
-
A common LRRK2 mutation in idiopathic Parkinson's disease.
Lancet. 2005 Jan 29-Feb 4;365(9457):415-6
PMID: 15680457
-
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7
PMID: 16269541
-
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1.
J Neurochem. 2007 Jul;102(1):93-102
PMID: 17394548
-
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain.
Cell Signal. 2006 Jun;18(6):910-20
PMID: 16243488
-
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
Neurobiol Dis. 2006 Aug;23(2):329-41
PMID: 16750377
-
Kinase activity of mutant LRRK2 mediates neuronal toxicity.
Nat Neurosci. 2006 Oct;9(10):1231-3
PMID: 16980962
-
The Parkinson disease gene LRRK2: evolutionary and structural insights.
Mol Biol Evol. 2006 Dec;23(12):2423-33
PMID: 16966681
-
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
Hum Mol Genet. 2007 Jan 15;16(2):223-32
PMID: 17200152
-
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
Biochemistry. 2007 Feb 6;46(5):1380-8
PMID: 17260967
-
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
Hum Mol Genet. 2006 Jan 15;15(2):223-32
PMID: 16321986